Pathological evaluation of radiotherapy and concomitant intraarterial cisplatin for maxillary sinus cancer
Pathological evaluation of radiotherapy and concomitant intraarterial cisplatin for maxillary sinus cancer
复制标题
上颌窦癌放疗联合动脉注射顺铂的病理学评价
DOI：
10.1016/j.anl.2020.04.004
复制
发表时间：
2020
影响因子：
1.7
通讯作者：
Nishizaki Kazunori
中科院分区：
文献类型：
--
作者：
Makino Takuma;Tachibana Tomoyasu;Kariya Shin;Matsui Yusuke;Matsuzaki Hidenobu;Fujimoto Shohei;Orita Yorihisa;Katsui Kuniaki;Hiraki Takao;Sato Yasuharu;Kanazawa Susumu;Nishizaki Kazunori
自2010年以来，我们主要对局部晚期上颌窦癌（MSC）进行放疗和伴随动脉内顺铂（RADPLAT）的手术治疗。本研究探讨治疗结果和病理评价后RADPLAT为MSC.MethodsPathological反应RADPLAT进行了评估，使用手术标本。根据Shimosato在1964年报告的分类方法，将病理学反应分级为V级（任何切片中均无肿瘤细胞残留）、IV级、III级、II级、I级和0级。使用Kaplan-Meier方法估计5年总体和疾病特异性生存率。采用卡方检验或Fisher精确检验对MSC复发与其他临床病理参数的相关性进行单因素分析。结果19例患者入选本研究，5例为T3期，14例为T4期。1例局部复发，3例远处转移。5年总生存率为67.1%（T3，50.0%; T4，69.6%），5年疾病特异性生存率为81.9%（T3，100%; T4，76.0%）。9例病例的组织学反应被归类为V级。没有显着的危险因素残留canceradiding.ConclusionOur研究表明，RADPLAT不仅具有低风险的副作用，但也可以代表一个有效的程序，局部晚期MSC的病理评估。增加RADPLAT的治疗强度可能提供一种有效的方式，以避免高侵入性手术。
ObjectiveSince 2010, we have mainly performed surgical treatment following radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for locally advanced maxillary sinus cancer (MSC). The present study investigated treatment results and pathological evaluations following RADPLAT for MSC.MethodsPathological response to RADPLAT was evaluated using surgical specimens. Pathological response was graded in accordance with the classification method that Shimosato reported in 1964, as grade V (no tumor cells remain in any of section), grade IV, III, II, I, and 0. Five-year overall and disease-specific survival rates were estimated using Kaplan-Meier methods. Univariate analyses of correlations between recurrence of MSC and other clinicopathological parameters were evaluated using the chi-square or Fisher's exact tests.Result19 patients were enrolled in this study, 5 patients showed T3 disease and 14 had T4 disease. One patient demonstrated local recurrence and 3 patients experienced distant metastasis. The 5-year overall survival rate was 67.1% (T3, 50.0%; T4, 69.6%), and the 5-year disease-specific survival rate was 81.9% (T3, 100%; T4, 76.0%). Histological response was categorized as grade V in 9 cases. No significant risk factors for residual cancer were identified.ConclusionOur study suggested that RADPLAT not only has a low risk of side effects, but also could represent an effective procedure for locally advanced MSC by pathological evaluation. Increasing the therapeutic intensity of RADPLAT might provide an effective modality to avoid highly invasive surgery.